• WuXi Biologics attended CPHI Milan 2026, meeting biopharma partners to promote its integrated CRDMO platform for complex biologics.
• Highlighted European manufacturing footprint in Dundalk, Ireland, and Wuppertal, Germany, positioning it as a regional supply option.
• Pointed to a global network across Ireland, Germany, the US, China, and Singapore to support dual-sourcing supply strategies.
• Disclosed quality track record as of June 2026: 49 regulatory inspections, 166 facility license approvals, over 2,000 GMP client audits.
• Reiterated execution metrics: 66 DNA-to-IND projects within six months, technology transfer to PPQ in as little as 3.5 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN67694) on October 09, 2026, and is solely responsible for the information contained therein.